Trial Profile
Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination With Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination With Ipilimumab 3 mg/kg in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; BMS 986192
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms CheckMate 511
- Sponsors Bristol-Myers Squibb
- 08 Mar 2024 This trial has been completed in Italy, According to European Clinical Trials Database record.
- 13 Sep 2022 Results of pooled-analysis of immune checkpoint inhibitor (ICI) trials (CheckMate [CM] 066, 067, 069 & 511) presented at the 47th European Society for Medical Oncology Congress
- 19 Nov 2021 Status changed from active, no longer recruiting to completed.